Altered smallpox vaccine shows efficacy in advanced liver cancer

02/13/2013 | Bloomberg Businessweek

Advanced liver cancer patients who received high doses of a modified version of Jennerex's smallpox vaccine Pexa-Vec had a median survival of 14.1 months following injection compared with 6.7 months in those who had low-dose shots, researchers reported in Nature Medicine. Researchers also found 35% of patients treated with high doses were alive 18 months later.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations